Evolution and expansion of multidrug-resistant malaria in southeast Asia: a genomic epidemiology study.
Alleles
Antimalarials
/ therapeutic use
Artemisinins
/ therapeutic use
Asia, Southeastern
/ epidemiology
Drug Resistance, Multiple
/ genetics
Drug Therapy, Combination
Genome-Wide Association Study
Humans
Malaria, Falciparum
/ drug therapy
Membrane Transport Proteins
/ genetics
Mutation
Phylogeny
Phylogeography
Plasmodium falciparum
/ drug effects
Protozoan Proteins
/ genetics
Quinolines
/ therapeutic use
Whole Genome Sequencing
Journal
The Lancet. Infectious diseases
ISSN: 1474-4457
Titre abrégé: Lancet Infect Dis
Pays: United States
ID NLM: 101130150
Informations de publication
Date de publication:
09 2019
09 2019
Historique:
received:
11
05
2019
revised:
15
06
2019
accepted:
20
06
2019
pubmed:
28
7
2019
medline:
13
6
2020
entrez:
27
7
2019
Statut:
ppublish
Résumé
A multidrug-resistant co-lineage of Plasmodium falciparum malaria, named KEL1/PLA1, spread across Cambodia in 2008-13, causing high rates of treatment failure with the frontline combination therapy dihydroartemisinin-piperaquine. Here, we report on the evolution and spread of KEL1/PLA1 in subsequent years. For this genomic epidemiology study, we analysed whole genome sequencing data from P falciparum clinical samples collected from patients with malaria between 2007 and 2018 from Cambodia, Laos, northeastern Thailand, and Vietnam, through the MalariaGEN P falciparum Community Project. Previously unpublished samples were provided by two large-scale multisite projects: the Tracking Artemisinin Resistance Collaboration II (TRAC2) and the Genetic Reconnaissance in the Greater Mekong Subregion (GenRe-Mekong) project. By investigating genome-wide relatedness between parasites, we inferred patterns of shared ancestry in the KEL1/PLA1 population. We analysed 1673 whole genome sequences that passed quality filters, and determined KEL1/PLA1 status in 1615. Before 2009, KEL1/PLA1 was only found in western Cambodia; by 2016-17 its prevalence had risen to higher than 50% in all of the surveyed countries except for Laos. In northeastern Thailand and Vietnam, KEL1/PLA1 exceeded 80% of the most recent P falciparum parasites. KEL1/PLA1 parasites maintained high genetic relatedness and low diversity, reflecting a recent common origin. Several subgroups of highly related parasites have recently emerged within this co-lineage, with diverse geographical distributions. The three largest of these subgroups (n=84, n=79, and n=47) mostly emerged since 2016 and were all present in Cambodia, Laos, and Vietnam. These expanding subgroups carried new mutations in the crt gene, which arose on a specific genetic background comprising multiple genomic regions. Four newly emerging crt mutations were rare in the early period and became more prevalent by 2016-17 (Thr93Ser, rising to 19·8%; His97Tyr to 11·2%; Phe145Ile to 5·5%; and Ile218Phe to 11·1%). After emerging and circulating for several years within Cambodia, the P falciparum KEL1/PLA1 co-lineage diversified into multiple subgroups and acquired new genetic features, including novel crt mutations. These subgroups have rapidly spread into neighbouring countries, suggesting enhanced fitness. These findings highlight the urgent need for elimination of this increasingly drug-resistant parasite co-lineage, and the importance of genetic surveillance in accelerating malaria elimination efforts. Wellcome Trust, Bill & Melinda Gates Foundation, UK Medical Research Council, and UK Department for International Development.
Sections du résumé
BACKGROUND
A multidrug-resistant co-lineage of Plasmodium falciparum malaria, named KEL1/PLA1, spread across Cambodia in 2008-13, causing high rates of treatment failure with the frontline combination therapy dihydroartemisinin-piperaquine. Here, we report on the evolution and spread of KEL1/PLA1 in subsequent years.
METHODS
For this genomic epidemiology study, we analysed whole genome sequencing data from P falciparum clinical samples collected from patients with malaria between 2007 and 2018 from Cambodia, Laos, northeastern Thailand, and Vietnam, through the MalariaGEN P falciparum Community Project. Previously unpublished samples were provided by two large-scale multisite projects: the Tracking Artemisinin Resistance Collaboration II (TRAC2) and the Genetic Reconnaissance in the Greater Mekong Subregion (GenRe-Mekong) project. By investigating genome-wide relatedness between parasites, we inferred patterns of shared ancestry in the KEL1/PLA1 population.
FINDINGS
We analysed 1673 whole genome sequences that passed quality filters, and determined KEL1/PLA1 status in 1615. Before 2009, KEL1/PLA1 was only found in western Cambodia; by 2016-17 its prevalence had risen to higher than 50% in all of the surveyed countries except for Laos. In northeastern Thailand and Vietnam, KEL1/PLA1 exceeded 80% of the most recent P falciparum parasites. KEL1/PLA1 parasites maintained high genetic relatedness and low diversity, reflecting a recent common origin. Several subgroups of highly related parasites have recently emerged within this co-lineage, with diverse geographical distributions. The three largest of these subgroups (n=84, n=79, and n=47) mostly emerged since 2016 and were all present in Cambodia, Laos, and Vietnam. These expanding subgroups carried new mutations in the crt gene, which arose on a specific genetic background comprising multiple genomic regions. Four newly emerging crt mutations were rare in the early period and became more prevalent by 2016-17 (Thr93Ser, rising to 19·8%; His97Tyr to 11·2%; Phe145Ile to 5·5%; and Ile218Phe to 11·1%).
INTERPRETATION
After emerging and circulating for several years within Cambodia, the P falciparum KEL1/PLA1 co-lineage diversified into multiple subgroups and acquired new genetic features, including novel crt mutations. These subgroups have rapidly spread into neighbouring countries, suggesting enhanced fitness. These findings highlight the urgent need for elimination of this increasingly drug-resistant parasite co-lineage, and the importance of genetic surveillance in accelerating malaria elimination efforts.
FUNDING
Wellcome Trust, Bill & Melinda Gates Foundation, UK Medical Research Council, and UK Department for International Development.
Identifiants
pubmed: 31345709
pii: S1473-3099(19)30392-5
doi: 10.1016/S1473-3099(19)30392-5
pmc: PMC6715858
pii:
doi:
Substances chimiques
Antimalarials
0
Artemisinins
0
Membrane Transport Proteins
0
PfCRT protein, Plasmodium falciparum
0
Protozoan Proteins
0
Quinolines
0
artenimol
6A9O50735X
piperaquine
A0HV2Q956Y
Types de publication
Journal Article
Research Support, N.I.H., Intramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
943-951Subventions
Organisme : Wellcome Trust
ID : 203141
Pays : United Kingdom
Organisme : Medical Research Council
ID : G0600718
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 206194
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 098051
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 090770
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/M006212/1
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 204911
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 204911/Z/16/Z
Pays : United Kingdom
Commentaires et corrections
Type : CommentIn
Type : CommentIn
Type : CommentIn
Informations de copyright
Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved.
Références
Parasitol Int. 2009 Sep;58(3):201-9
pubmed: 19393762
N Engl J Med. 2009 Jul 30;361(5):455-67
pubmed: 19641202
Lancet. 2012 May 26;379(9830):1960-6
pubmed: 22484134
Nature. 2012 Jul 19;487(7407):375-9
pubmed: 22722859
Lancet Infect Dis. 2012 Nov;12(11):851-8
pubmed: 22940027
Antimicrob Agents Chemother. 2013 Feb;57(2):818-26
pubmed: 23208711
Nat Genet. 2013 Jun;45(6):648-55
pubmed: 23624527
Nature. 2014 Jan 2;505(7481):50-5
pubmed: 24352242
Proc Natl Acad Sci U S A. 2014 Apr 29;111(17):E1759-67
pubmed: 24728833
N Engl J Med. 2014 Jul 31;371(5):411-23
pubmed: 25075834
Nat Genet. 2015 Mar;47(3):226-34
pubmed: 25599401
Nature. 2015 Oct 8;526(7572):207-211
pubmed: 26375008
Lancet Infect Dis. 2016 Mar;16(3):357-65
pubmed: 26774243
Elife. 2016 Mar 04;5:null
pubmed: 26943619
Lancet Infect Dis. 2017 Feb;17(2):164-173
pubmed: 27818095
Lancet Infect Dis. 2017 Feb;17(2):174-183
pubmed: 27818097
Malar J. 2016 Dec 20;15(1):597
pubmed: 27998271
Malar J. 2017 Jan 13;16(1):27
pubmed: 28086775
Lancet Infect Dis. 2017 May;17(5):491-497
pubmed: 28161569
Emerg Infect Dis. 2017 Apr;23(4):715-717
pubmed: 28322709
MBio. 2017 May 9;8(3):
pubmed: 28487425
J Infect Dis. 2017 Aug 15;216(4):468-476
pubmed: 28931241
Lancet Infect Dis. 2017 Oct;17(10):1022-1023
pubmed: 28948924
Lancet Infect Dis. 2018 Mar;18(3):337-345
pubmed: 29398391
Antimicrob Agents Chemother. 2018 Mar 27;62(4):
pubmed: 29439977
Nat Commun. 2018 May 2;9(1):1769
pubmed: 29720620
Nat Commun. 2018 Aug 17;9(1):3314
pubmed: 30115924
Lancet Infect Dis. 2019 Sep;19(9):952-961
pubmed: 31345710